N NAGARANI | Toxicology | Best Researcher Award

Posted on by ScienceFather

Dr. N NAGARANI | Toxicology | Best Researcher Award

Assistant Professor, Fatima College (Autonomous) Madurai India

Dr. N. Nagarani, an Assistant Professor in Zoology, is a passionate educator and researcher with expertise in marine biology, toxicology, pharmacology, and environmental biology. Born on February 2, 1980, she is proficient in English and Tamil and has contributed to both academic and research advancements. With over a decade of experience in teaching at Fatima College, Madurai, and St. Antony’s College, Dindigul, she has also worked as a Research Associate at Madurai Kamaraj University. She has actively participated in various national and international seminars and workshops. Dr. Nagarani’s research focuses on the application of biomarkers and toxicology in marine life.

Publication Profile

Google Scholar

🎓 Education

Dr. Nagarani completed her undergraduate degree in Zoology from Sri Meenakshi Govt. College for Women, Madurai in 2000. She pursued her postgraduate degree in Integrated Biology from Madurai Kamaraj University (2002), followed by a B.Ed. in Biological Science (2004) from Thiagarajar College. Her Ph.D. in Environmental Science was awarded by the Department of Marine & Coastal Studies at Madurai Kamaraj University in 2010. In addition, she holds a Diploma in P.BED DSA (2005) and a SET in Life Science (2016).

🧑‍🏫 Experience

Dr. N. Nagarani has extensive experience in both teaching and research. She started her teaching career at the Department of Marine & Coastal Studies, Madurai Kamaraj University (2010-2011) and has taught at St. Antony’s College (2017-2018) and Fatima College (2018-present). As a Research Associate at Madurai Kamaraj University (2013-2016), she contributed significantly to marine and coastal research. She has also held roles such as Board of Studies member and NAAC Committee member at St. Antony’s College and participated in numerous seminars and workshops.

🏆 Awards & Honors

Dr. Nagarani’s academic excellence has been recognized throughout her career. She received the University Rank Holder (Third) award from Madurai Kamaraj University in 2000. She was honored with fellowships such as the USRF and CSIR Research Associate. Her contributions to research were acknowledged with several awards in national and international conferences. She also received sponsorship from various academic bodies and has actively participated in organizing multiple academic events, workshops, and symposia in her field.

🔬 Research Focus

Dr. Nagarani’s primary research interests lie in marine biology, toxicology, pharmacology, biomarkers techniques, and environmental biology. Her work in environmental science includes assessing the impact of pollutants on marine ecosystems through biomarker approaches. She has contributed significantly to understanding marine plant-based antioxidant activities and environmental monitoring. Dr. Nagarani’s research extends to the development of ecological indices for environmental sustainability and studying the effects of marine toxins on local biodiversity.

🏆Conclusion 

Dr. N. Nagarani exhibits a strong academic and research background, especially in environmental and marine studies, making her highly suitable for the Best Researcher Award. With further focus on publishing in high-impact journals and international collaborations, she has the potential to significantly contribute to the scientific community. Her dedication to education and research reflects her passion for advancing the field of environmental science.

Publication Top Notes

  • Cadmium and copper toxicity in three marine macroalgae: evaluation of the biochemical responses and DNA damage
    • Year: 2014
    • Authors: MY Babu, L Palanikumar, N Nagarani, VJ Devi, SR Kumar, …
    • Citation: 58

 

  • A study of proteotoxicity and genotoxicity induced by the pesticide and fungicide on marine invertebrate (Donax faba)
    • Year: 2013
    • Authors: V JanakiDevi, N Nagarani, M YokeshBabu, AK Kumaraguru, …
    • Citation: 52

 

  • Identification of DNA damage in marine fish Therapon jarbua by comet assay technique
    • Year: 2012
    • Authors: N Nagarani, VJ Devi, AK Kumaraguru
    • Citation: 40

 

  • Screening, isolation and characterization of protease producing moderately halophilic microorganism Halomonas meridiana associated with coral mucus
    • Year: 2014
    • Authors: R Anithajothi, N Nagarani, G Umagowsalya, K Duraikannu, …
    • Citation: 27

 

  • Evaluation of anti-inflammatory, antidiabetic, cytotoxic activity of Kappaphycus alvarezii
    • Year: 2013
    • Authors: N Nagarani, AK Kumaraguru
    • Citation: 27

 

  • Mercuric chloride induced proteotoxicity and structural destabilization in marine fish (Therapon jarbua)
    • Year: 2011
    • Authors: N Nagarani, VJ Devi, AK Kumaraguru
    • Citation: 26

 

  • Investigation of the effect of K. alvarezii on antioxidant enzymes, cell viability and DNA damage in male rats
    • Year: 2012
    • Authors: N Nagarani, AK Kumaraguru
    • Citation: 21

 

  • Genotoxicity Assessment of Mercuric Chloride in the Marine Fish Therapon jaruba
    • Year: 2009
    • Author: N Nagarani
    • Citation: 20

 

  • Protective effect of Kappaphycus alvarezii (Rhodophyta) extract against DNA damage induced by mercury chloride in marine fish
    • Year: 2012
    • Authors: N Nagarani, V JanakiDevi, M YokeshBabu, AK Kumaraguru
    • Citation: 16

 

  • Genotoxic effects of profenofos on the marine fish, Therapon jarbua
    • Year: 2012
    • Authors: V Janaki Devi, N Nagarani, M Yokesh Babu, N Vijayalakshimi, …
    • Citation: 15

 

  • Occupational health effects due to nickel and chromium exposure in electroplating workers
    • Year: 2012
    • Authors: S Jeyamala, AK Kumaraguru, N Nagarani
    • Citation: 14

 

  • Investigation of acute toxicity of heavy metals in Artemia salina acclimated to different salinity
    • Year: 2012
    • Authors: R Umarani, AK Kumaraguru, N Nagarani
    • Citation: 14

 

  • Biosynthesis of silver nanoparticles from seaweed associated marine bacterium and its antimicrobial activity against UTI pathogens
    • Year: 2013
    • Authors: M YokeshBabu, V JanakiDevi, CM Ramakritinan, R Umarani, N Nagarani, …
    • Citation: 12

 

 

 

Daniela Malengo | Pharmacology | Women Researcher Award

Posted on by ScienceFather

Dr. Daniela Malengo | Pharmacology | Women Researcher Award

Dr at Istituto Europeo di Oncologia, Italy

Daniela Malengo, an Italian pharmacist, is currently the Vice Director of the Hospital Pharmacy Division at Istituto Europeo di Oncologia, Milan. With a career spanning over 15 years, Daniela specializes in oncology drug management, hospital pharmacy administration, and medical device protocols. She is passionate about optimizing pharmaceutical practices and contributing to oncology care. Throughout her career, she has been dedicated to ensuring the safe and effective use of drugs in oncological treatments and has supported numerous research projects. Her leadership skills also extend to teaching pharmacy students through internships and projects.

Profile

Scopus

🎓 Education 

Management of CAR-T Patients, LIUC Business School (Dec 2023–Mar 2024). Hospital Pharmacy Management, Università Bocconi, Milan (Sept 2019–Dec 2020). Specialization in Applied Pharmacology, University of Pavia (2005–2009). Degree in Pharmacy, University of Pavia (2000–2005). State Exam for Pharmacist License, University of Pavia (Nov–Dec 2005). Scientific High School Diploma, Liceo Scientifico N. Copernico, Pavia (1995–2000)

💼 Experience

Vice Director of Hospital Pharmacy Division, Istituto Europeo di Oncologia, Milan (July 2023–Present): Managing narcotic drug dispensation and overseeing oncological therapy. Assistant Pharmacist, Istituto Europeo di Oncologia, Milan (Mar 2011–July 2023): Managed medical devices and chemotherapy prescriptions. Pharmacist – Research Fellow, Istituto Europeo di Oncologia, Milan (May 2006–Feb 2011): Supervised experimental drugs and contributed to research on oncological drug appropriateness. Intern (2004–2005): Worked at Farmacia Dott. A. Lodola, Siziano, dispensing medications to the public.

🏆 Awards & Honors

Numerous presentations at national congresses, including SIFO Congress (2009–2010). Recognized for contributions to hospital pharmacy management and cost analysis of oncological treatments. Leadership roles in pharmacy student internships and research programs. Awarded for excellence in promoting safe oncological drug usage.

🔬 Research Focus

Oncology Pharmacology: Focuses on managing oncological drug appropriateness, chemotherapy prescriptions, and medical device protocols. Pharmacy Management: Expertise in hospital pharmacy operations, including drug dispensation, quality control, and patient safety. Experimental Pharmacology: Managed experimental drugs and contributed to clinical research in oncological treatments. Cost Analysis: Focus on managing hospital pharmacy expenses and evaluating drug cost-effectiveness.

Conclusion

Daniela Malengo’s career exemplifies dedication to hospital pharmacy, oncological drug management, and the advancement of healthcare systems through her research and leadership roles. Her consistent contributions to improving patient outcomes in oncology, coupled with her academic excellence, make her a strong candidate for the Women Researcher Award. With her continued focus on improving the quality of healthcare services and mentoring future professionals, Daniela’s future contributions are poised to have a lasting impact in both the pharmacy and healthcare sectors.

📚Publications 

  • The Prolonged Clinical Benefit with Metronomic Chemotherapy (VEX Regimen) in Metastatic Breast Cancer Patients
    • Authors: Montagna, E., Pagan, E., Cancello, G., Viale, G., Colleoni, M.
    • Journal: Anti-Cancer Drugs
    • Volume: 33
    • Issue: 1
    • Pages: E628–E634
    • Year: 2022
    • Citations: 6

 

  • Management of Breast Cancer Patients During the Peak of the COVID-19 Pandemic
    • Authors: Montagna, E., Bellerba, F., Sangalli, C., Colleoni, M., Veronesi, P.
    • Journal: European Journal of Surgical Oncology
    • Volume: 47
    • Issue: 10
    • Pages: 2694–2695
    • Year: 2021
    • Citations: 2

 

Srijan Acharya | Molecular Pharmacology | Excellence in Research

Posted on by ScienceFather

Dr. Srijan Acharya | Molecular Pharmacology | Excellence in Research

Dr at St. Jude Children’s Research Hospital, United States

Srijan Acharya is a dedicated scientist with expertise in molecular pharmacology and cancer genomics. He is currently a Post-Doctoral Research Fellow at St. Jude Children’s Research Hospital, focusing on childhood cancer research. With 32 published scientific articles and a total citation count of over 385, his work has contributed significantly to biomarker discovery, receptor pharmacology, and immuno-oncology. His research aims to address therapeutic resistance in pediatric malignancies through small molecule screening. Srijan is fluent in English, Bangla, and Hindi, with basic knowledge of Korean.

Profile

Scholar

🎓 Education

PhD in Molecular Pharmacology from Chonnam National University, South Korea (2020). M.Sc. in Biotechnology from North South University, Bangladesh (2015). BPHRM in Pharmacy from East West University, Bangladesh (2012). His academic journey has provided a strong foundation in receptor pharmacology and molecular biology, guiding his transition into cancer research.

💼 Experience

Post-Doctoral Research Fellow, Pharmacy Department, St. Jude Children’s Research Hospital, USA (2023-Present). Post-Doctoral Research Fellow, Pathology Department, Mitchell Cancer Institute, USA (2020-2023). Executive Officer, Research and Development, Square Pharmaceutical PLC, Bangladesh (2012-2013). His experience spans academia and industry, with a focus on cancer research, receptor signaling, and small molecule screening.

🏆 Awards and Honors

Inducted into Sigma Xi, The Scientific Research Honor Society (2023). Recognized in Who’s Who in America by Marquis (2023). Young Investigator Award at AACR conference by AAISCR (2022). Best Presenter Award from China Pharmaceutical University (2021). Global Scholarship from Chonnam National University, Korea (2015). These accolades reflect his significant contributions to molecular pharmacology and cancer research.

🔬 Research Focus

Srijan’s research primarily investigates the role of molecular signaling in cancer, focusing on the interaction of nicotine receptors with GPCRs and their impact on cancer progression. At St. Jude, his work focuses on childhood cancers, particularly Ewing sarcoma and rhabdomyosarcoma. He uses small molecule screening to discover potential therapeutic agents and aims to overcome therapeutic resistance in pediatric cancers.

Conclusion

Srijan Acharya is a highly accomplished and promising researcher whose contributions to cancer pharmacology and molecular biology are noteworthy. His interdisciplinary research approach, combined with his dedication to advancing pediatric oncology, positions him as a leader in the field. With continued mentorship and broader collaborative efforts, Acharya is well poised for even greater achievements, further solidifying his place as an influential scientist in the biomedical community.

📚Publications 

  • Title: Unveiling the intracellular dynamics of α4β2 nAChR-mediated ERK activation through the interplay of arrestin, Gβγ, and PKCβII
    Year: 2024
    Authors: Dooti K, Acharya S, Wang S, Kim K.M.

 

  • Title: Biphasic transcriptional and posttranscriptional regulation of MYB by androgen signaling mediates its growth control in prostate cancer
    Year: 2023
    Authors: Acharya S, Anand S, Khan MA, Zubair H, Srivastava SK, Singh S, Singh AP

 

  • Title: MYB exhibits racially disparate expression, clinicopathologic association, and predictive potential for biochemical recurrence in prostate cancer
    Year: 2023
    Authors: Md Khan, S Acharya, S Anand, F Sameeta, P Pramanik, C Keel, S Singh, James E Carter, S Dasgupta, A Singh

 

  • Title: Comparative study of the molecular mechanisms underlying the G protein and β-arrestin-dependent pathways that lead to ERKs activation upon stimulation by dopamine D2 receptor
    Year: 2023
    Authors: Liu H, Acharya S, Sudan SK, Hu L, Wu C, Cao Y, Li H, Zhang X

 

  • Title: Frequent loss of cacna1c, a calcium voltage-gated channel subunit is associated with lung adenocarcinoma progression and poor prognosis
    Year: 2023
    Authors: Dasgupta, S., Acharya, S., Khan, M. A., Pramanik, P., Marbut, S. M., Yunus, F., Galeas, J. N., Singh, S., Singh, A. P., and Dasgupta, S.

 

  • Title: Nicotine causes alternative polarization of macrophages via Src-mediated STAT3 activation: Potential pathobiological implications
    Year: 2022
    Authors: Acharya S, Saranyutanon S, Deshmukh SK, Khan MA, Singh S, Singh AP

 

  • Title: β-Arrestin1 and GRK2 play permissive roles in Src-mediated endocytosis of α4β2 nicotinic acetylcholine receptor
    Year: 2021
    Authors: Acharya S, Kundu D, Kim KM

 

  • Title: Roles of the Functional Interaction between Brain Cholinergic and Dopaminergic Systems in the Pathogenesis and Treatment of Schizophrenia and Parkinson’s Disease
    Year: 2021
    Authors: Acharya S, Kim KM

 

  • Title: Clinicopathologic significance and race-specific prognostic association of MYB overexpression in ovarian cancer
    Year: 2021
    Authors: Miree, O., Srivastava, …Acharya S.et al.

 

  • Title: Metabotropic signaling cascade involved in α4β2 nicotinic acetylcholine receptor-mediated PKCβII activation
    Year: 2020
    Authors: Acharya S, D. Kundu, H.J. Choi, and K.M. Kim

 

  • Title: Catalpol and Mannitol, Two Components of Rehmannia glutinosa, Exhibit Anticonvulsant Effects Probably via GABAA Receptor Regulation
    Year: 2019
    Authors: Acharya S, Kim M., Botanas C. J., Custodio R. J., Lee H. J., Sayson L. V., Kim H. J.

 

  • Title: Design, synthesis and in vitro activity of 1,4-disubstituted piperazines and piperidines as triple reuptake inhibitors
    Year: 2017
    Authors: Paudel S, Acharya S, Yoon G, Kim K.M., & Cheon S.H.